Quantcast
 
New ETF Book by Larry Connors - Click here to read more


IDMI

Takeda commences tender offer to acquire IDM Pharma - 05/27 - 02:16 PM ET

CORRECTING and REPLACING Takeda Commences Cash Tender Offer for All Outstanding Shares of IDM Pharma, Inc. - 05/26 - 10:59 AM ET

Finkelstein Thompson LLP Announces Investigation of IDM Pharma, Inc. - 05/20 - 05:40 PM ET

IDM Pharma Reports First Quarter Financial Results - 05/11 - 07:30 AM ET

IDM Pharma, Inc. - Financial and Strategic Analysis Review - 05/04 - 05:20 PM ET

PennyStockChaser.com: IDM Pharma, Inc. (NASDAQ: IDMI) on the Move - 04/13 - 12:55 PM ET

IDM Pharma Receives Nasdaq Shareholder Equity Notification - 04/13 - 07:30 AM ET

IDM Pharma Complies With NASDAQ Marketplace Rule 4350(b)(1)(B) and Announces Filing of Annual Report on Form 10-K for 2008 Fiscal Year Containing Audit Opinion With Going Concern Qualification - 04/03 - 07:30 AM ET

GreenArrowStock.com: Check Us Out GreenArrowStock.com: IDMI reports financial results for 2008 - 03/31 - 10:27 AM ET

IDM Pharma Reports 2008 Financial Results - 03/31 - 07:30 AM ET

www.companiesandmarkets.com: IDM Pharma Inc-Detailed Product Pipeline - 03/16 - 02:10 PM ET

QualityStocks: QualityStocks News - IDM Pharma, Inc. (IDMI) Announces Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma - 3/10/09 - 03/12 - 04:41 AM ET

IDM Pharma wins European approval for osteosarcoma drug - 03/10 - 09:44 AM ET

IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma - 03/09 - 03:42 PM ET

IDM Pharma Joins NORD to Raise Awareness of Rare Diseases - 02/26 - 08:00 AM ET

www.companiesandmarkets.com: IDM Pharma Inc-Financial Company Report - 02/18 - 07:32 AM ET

www.companiesandmarkets.com: IDM Pharma, Inc.-Deals & Alliances Report - 02/11 - 10:56 AM ET

IDM Pharma wins European positive opinion for osteosarcoma drug - 12/19 - 12:02 PM ET

BRIEF-IDM Pharma provides update on Mifamurtide European regulatory status - 12/18 - 01:38 PM ET

IDM Pharma Provides Update on Mifamurtide (MEPACT(R), L-MTP-PE) European Regulatory Status - 12/18 - 01:32 PM ET

Page 1 of 1     1     Previous  |  Next

<< Back to Stock Index

 

Most Popular News
  UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
* Attendance is strictly limited and are filled on a first-come, first-served basis.
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.